Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ecteinascidin-743.

Jeanne Held-Warmkessel1

  • 1J_Warmkessel@fccc.edu

Clinical Journal of Oncology Nursing
|June 10, 2003
PubMed
Summary

Ecteinascidin-743 (ET-743), a marine-derived cancer drug, is being tested in clinical trials for solid tumors. Monitoring liver function is key to managing side effects like myelosuppression and hepatotoxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Looking into hyperthermic intraperitoneal chemotherapy.

Nursing·2014
Same author

A patient with tumor lysis syndrome.

Oncology (Williston Park, N.Y.)·2014
Same author

Lactic acidosis in patients with cancer.

Clinical journal of oncology nursing·2014
Same author

Gemcitabine-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.

Oncology nursing forum·2014
Same author

Care of the open abdomen after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.

Oncology nursing forum·2014
Same author

Non-small cell lung cancer: recent advances.

Nursing·2014

Area of Science:

  • Marine biotechnology
  • Pharmacology
  • Oncology

Background:

  • Ecteinascidin-743 (ET-743) is a novel marine-derived antineoplastic agent.
  • Clinical trials are evaluating its efficacy in treating various solid tumors.

Purpose of the Study:

  • To review the clinical trial progress of ET-743.
  • To highlight key toxicities and nursing considerations for ET-743 administration.

Main Methods:

  • Phase I and II clinical trial data review.
  • Analysis of adverse events and patient management strategies.

Main Results:

  • ET-743 has shown promise in phase II trials for solid tumors.
  • Common side effects include myelosuppression, hepatotoxicity, nausea, and vomiting.
  • Liver function tests are critical for predicting and managing toxicities.

Conclusions:

  • ET-743 is a significant marine-derived agent for solid tumor treatment.
  • Close monitoring of liver function and patient education are essential for safe and effective use.
  • Further research and ongoing trials continue to explore ET-743's potential.

Related Experiment Videos